Join us tonight for #SABCSUpdate #1! 💬 Datopotamab Deruxtecan for HR+/HER2– Breast Cancer: Results From the Phase 3 TROPION-Breast01 Trial 👥 Aditya Bardia, MD, Marija Sullivan, MD, & Megan E. Tesch 🕓 4:00 PM EST 📆 bit.ly/4a5bxX7

It's almost time for #SABCSUpdates #2! 💬 Neoadjuvant/adjuvant pembrolizumab for HR+/HER2– EBC: results from the phase 3 KEYNOTE-756 trial 👥 Maryam Lustberg MD, MPH, FASCO, Adriana Kahn, MD, & Dionisia Quiroga, DO, PhD, FASCO 🕓 4:00 PM EST 📆 bit.ly/47KLEKx

We're aware that there may be some issues seeing the video. Here's the link to that video: youtu.be/Tqg541PXTb0

Integrity CE SoMe CME Adriana Kahn, MD Dionisia Quiroga, DO, PhD, FASCO KEYNOTE-756 Primary Endpoint (pCR) pCR benefit w/ neo/adj pembro across multiple definitions of pCR in KN756   pCR, % ypT0/Tis ypN0 (primary endpoint): 24 vs 16 ypT0 ypN0: 21 vs 13 ypT0/Tis: 29 vs 18   #SABCSUpdates #bcsm

Integrity CE SoMe CME Adriana Kahn, MD Dionisia Quiroga, DO, PhD, FASCO KEYNOTE-756 LN & Stage Subgroup Analysis Larger magnitude of pCR benefit w/ neo/adj pembro & N+ disease in KN756   Subgroup pCR, % LN+: 25 vs 16 LN–: 17 vs 13 Stage II: 26 vs 17 Stage III: 22 vs 14   #SABCSUpdates

1/ 📽️ Case discussion: What is the SOC for inoperable stage III NSCLC❓ Ticiana Batista (Leal) covers it all in the video below❗️ #Stage3NSCLCBrief #LungCancer vimeo.com/894957998/7def…

2/ #Stage3NSCLCBrief SOC therapy options for unresectable stage III NSCLC w/ Ticiana Batista (Leal), Kristin Higgins, & Aakash Desai, MD, MPH, FASCO Supported by an educational grant from AstraZeneca. CME ℹ️ bit.ly/3RwxBRX 📊 What is your specialty/degree❓

3/ Are you routinely using concurrent chemoRT w/ consolidation durvalumab for eligible patients w/ inoperable stage III NSCLC❓ #Stage3NSCLCBrief #LungCancer ✍️ National Comprehensive Cancer Network (NCCN) management of unresectable stage III NSCLC ⤵️

2/💬 Can we improve upon the PFS and OS benefits of SOC cCRT + DUR consolidation for inoperable stage III NSCLC❓ #Stage3NSCLCBrief #LungCancer

Tweeting at conferences isn’t frivolous (he said, preaching to choir ;) For me, it’s an aide-mémoire of what I’m learning, a means of engagement in the meta-meeting, and on-the-ground reporting for those who were unable to attend :) Really enjoyed #GI24 for all these reasons!

This is deeply heartbreaking news. Dr Mitchell was a deep friend to so many of us, a profoundly inspiring leader and groundbreaker for health equity. We deeply mourn her loss, and redouble our efforts for increasing health equity in cancer in her honor Dr. Rob Winn Amelie Ramirez

Upstate NY Cancer Symposium in June 2024! 1.5 days to focus and discuss SoC on the most commonly treated solid tumors and hematologic malignancies in the community. Register at bit.ly/3N7QYiW Faculty: Richard Dunne, MD Stephanie Graff, MD, FACP, FASCO Stephen V Liu, MD Shipra Gandhi @MattGalsky

✅This #TumorBoardTuesday🗣️with Mike Pishvaian & Johnathan Ebben MD, PhD is provided by Integrity CE, LLC 👍Supported by ed grants from Astellas, AstraZeneca, Bayer, Janssen, Lilly, Novartis, Seagen and Taiho Oncology🙏 Info about 🆓 CME: integrityce.com/TBT2024

#TumorBoardTuesday ➡️Before Shilpa Gupta & Jon Anker, MD, PhD🗣️2L TX following progression on enfortumab vedotin + pembrolizumab for #BladderCancer, tell us your connection to this medical🩺discussion 👇👇🏼👇🏾

#TumorBoardTuesday ➡️Before Maryam Lustberg MD, MPH, FASCO & Mridula George🗣️Tx options for AI-resistant HR+/HER2- #MBC, tell us your connection to this medical🩺discussion 👇👇🏼👇🏾

Breast Cancer HCPs please complete our 1 minute survey on the use of ctDNA for ER+ mBC patients and aligned treatment options. us14.list-manage.com/survey?u=12ee7…|*